AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Harrow, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Adrienne L. Graves of Harrow received a new equity compensation award on June 20, 2025, as reported in this Form 4 filing. The transaction details include:

  • Awarded 7,339 Restricted Stock Units (RSUs) with $0 exercise price
  • RSUs will vest fully on the one-year anniversary of the grant date
  • Underlying shares cannot be delivered, transferred, or sold until termination of service

This grant appears to be part of the company's director compensation program, representing a standard compensatory award for board service. The filing was submitted by Andrew R. Boll as Attorney in Fact for the director on June 24, 2025, within the required reporting window. Ms. Graves holds these RSUs under direct ownership.

La direttrice Adrienne L. Graves di Harrow ha ricevuto un nuovo premio di compensazione azionaria il 20 giugno 2025, come riportato in questo modulo Form 4. I dettagli della transazione includono:

  • Assegnazione di 7.339 Unità Azionarie Vincolate (RSU) con prezzo di esercizio pari a $0
  • Le RSU matureranno completamente al primo anniversario della data di assegnazione
  • Le azioni sottostanti non possono essere consegnate, trasferite o vendute fino alla cessazione del servizio

Questo premio sembra far parte del programma di compensazione dei direttori della società, rappresentando un premio compensativo standard per il servizio nel consiglio. La dichiarazione è stata presentata da Andrew R. Boll in qualità di Procuratore per la direttrice il 24 giugno 2025, entro i termini richiesti per la segnalazione. La signora Graves detiene queste RSU in proprietà diretta.

La directora Adrienne L. Graves de Harrow recibió un nuevo premio de compensación en acciones el 20 de junio de 2025, según se informó en este formulario Form 4. Los detalles de la transacción incluyen:

  • Otorgamiento de 7,339 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0
  • Las RSU se consolidarán completamente en el aniversario de un año desde la fecha de concesión
  • Las acciones subyacentes no pueden ser entregadas, transferidas o vendidas hasta la finalización del servicio

Esta concesión parece formar parte del programa de compensación para directores de la empresa, representando un premio compensatorio estándar por el servicio en la junta. La presentación fue realizada por Andrew R. Boll como Apoderado de la directora el 24 de junio de 2025, dentro del plazo requerido para el reporte. La Sra. Graves mantiene estas RSU bajo propiedad directa.

Adrienne L. Graves ì´ì‚¬ë‹˜ì€ Harrowì—서 2025ë…� 6ì›� 20ì� 새로ìš� ì£¼ì‹ ë³´ìƒ ìˆ˜ì—¬ë¥� 받았으며, ì´ëŠ” ë³� Form 4 ì œì¶œì„œì— ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�. 거래 세부 ì‚¬í•­ì€ ë‹¤ìŒê³� 같습니다:

  • 행사가ê²� $0ì� 7,339 제한 ì£¼ì‹ ë‹¨ìœ„(RSU) 수여
  • RSUëŠ� 수여ì¼ë¡œë¶€í„� 1주년 기ë…ì¼ì— ì „ì•¡ 베스íŒ�ë�
  • 기초 주ì‹ì€ 서비ìŠ� 종료 시까지 ì¸ë„, ì´ì „ ë˜ëŠ” íŒë§¤ê°€ 불가능함

ì´ë²ˆ 수여ëŠ� 회사ì� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì� ì¼ë¶€ë¡� ë³´ì´ë©�, ì´ì‚¬íš� ì„œë¹„ìŠ¤ì— ëŒ€í•� 표준 ë³´ìƒ ìˆ˜ì—¬ë¥� 나타냅니ë‹�. 해당 제출서는 2025ë…� 6ì›� 24ì� ì´ì‚¬ 대리ì¸ì� Andrew R. Bollì—� ì˜í•´ 규정ë� ë³´ê³  기간 ë‚´ì— ì œì¶œë˜ì—ˆìŠµë‹ˆë‹�. Graves ì´ì‚¬ëŠ� ì� RSUë¥� ì§ì ‘ 소유하고 있습니다.

La directrice Adrienne L. Graves de Harrow a reçu une nouvelle attribution de compensation en actions le 20 juin 2025, comme indiqué dans ce dépôt Form 4. Les détails de la transaction sont les suivants :

  • Attribution de 7 339 unités d’actions restreintes (RSU) avec un prix d’exercice de 0 $
  • Les RSU seront entièrement acquises à la date anniversaire d’un an à compter de la date d’attribution
  • Les actions sous-jacentes ne peuvent être livrées, transférées ou vendues avant la fin du service

Cette attribution semble faire partie du programme de rémunération des administrateurs de la société, représentant une récompense standard pour le service au conseil d’administration. Le dépôt a été soumis par Andrew R. Boll en tant que mandataire de la directrice le 24 juin 2025, dans le délai de déclaration requis. Mme Graves détient ces RSU en propriété directe.

Die Direktorin Adrienne L. Graves von Harrow erhielt am 20. Juni 2025 eine neue Aktienvergütung, wie in dieser Form 4-Meldung berichtet. Die Transaktionsdetails umfassen:

  • Zuteilung von 7.339 Restricted Stock Units (RSUs) mit einem Ausübungspreis von 0 $
  • Die RSUs werden vollständig am einjährigen Jahrestag des Gewährungsdatums vesten
  • Die zugrunde liegenden Aktien können bis zum Ausscheiden aus dem Dienst nicht geliefert, übertragen oder verkauft werden

Diese Zuteilung scheint Teil des Vergütungsprogramms für Direktoren des Unternehmens zu sein und stellt eine übliche Vergütung für die Tätigkeit im Vorstand dar. Die Meldung wurde am 24. Juni 2025 von Andrew R. Boll als Bevollmächtigter für die Direktorin innerhalb des vorgeschriebenen Meldefensters eingereicht. Frau Graves hält diese RSUs im Direktbesitz.

Positive
  • None.
Negative
  • None.

La direttrice Adrienne L. Graves di Harrow ha ricevuto un nuovo premio di compensazione azionaria il 20 giugno 2025, come riportato in questo modulo Form 4. I dettagli della transazione includono:

  • Assegnazione di 7.339 Unità Azionarie Vincolate (RSU) con prezzo di esercizio pari a $0
  • Le RSU matureranno completamente al primo anniversario della data di assegnazione
  • Le azioni sottostanti non possono essere consegnate, trasferite o vendute fino alla cessazione del servizio

Questo premio sembra far parte del programma di compensazione dei direttori della società, rappresentando un premio compensativo standard per il servizio nel consiglio. La dichiarazione è stata presentata da Andrew R. Boll in qualità di Procuratore per la direttrice il 24 giugno 2025, entro i termini richiesti per la segnalazione. La signora Graves detiene queste RSU in proprietà diretta.

La directora Adrienne L. Graves de Harrow recibió un nuevo premio de compensación en acciones el 20 de junio de 2025, según se informó en este formulario Form 4. Los detalles de la transacción incluyen:

  • Otorgamiento de 7,339 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0
  • Las RSU se consolidarán completamente en el aniversario de un año desde la fecha de concesión
  • Las acciones subyacentes no pueden ser entregadas, transferidas o vendidas hasta la finalización del servicio

Esta concesión parece formar parte del programa de compensación para directores de la empresa, representando un premio compensatorio estándar por el servicio en la junta. La presentación fue realizada por Andrew R. Boll como Apoderado de la directora el 24 de junio de 2025, dentro del plazo requerido para el reporte. La Sra. Graves mantiene estas RSU bajo propiedad directa.

Adrienne L. Graves ì´ì‚¬ë‹˜ì€ Harrowì—서 2025ë…� 6ì›� 20ì� 새로ìš� ì£¼ì‹ ë³´ìƒ ìˆ˜ì—¬ë¥� 받았으며, ì´ëŠ” ë³� Form 4 ì œì¶œì„œì— ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�. 거래 세부 ì‚¬í•­ì€ ë‹¤ìŒê³� 같습니다:

  • 행사가ê²� $0ì� 7,339 제한 ì£¼ì‹ ë‹¨ìœ„(RSU) 수여
  • RSUëŠ� 수여ì¼ë¡œë¶€í„� 1주년 기ë…ì¼ì— ì „ì•¡ 베스íŒ�ë�
  • 기초 주ì‹ì€ 서비ìŠ� 종료 시까지 ì¸ë„, ì´ì „ ë˜ëŠ” íŒë§¤ê°€ 불가능함

ì´ë²ˆ 수여ëŠ� 회사ì� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì� ì¼ë¶€ë¡� ë³´ì´ë©�, ì´ì‚¬íš� ì„œë¹„ìŠ¤ì— ëŒ€í•� 표준 ë³´ìƒ ìˆ˜ì—¬ë¥� 나타냅니ë‹�. 해당 제출서는 2025ë…� 6ì›� 24ì� ì´ì‚¬ 대리ì¸ì� Andrew R. Bollì—� ì˜í•´ 규정ë� ë³´ê³  기간 ë‚´ì— ì œì¶œë˜ì—ˆìŠµë‹ˆë‹�. Graves ì´ì‚¬ëŠ� ì� RSUë¥� ì§ì ‘ 소유하고 있습니다.

La directrice Adrienne L. Graves de Harrow a reçu une nouvelle attribution de compensation en actions le 20 juin 2025, comme indiqué dans ce dépôt Form 4. Les détails de la transaction sont les suivants :

  • Attribution de 7 339 unités d’actions restreintes (RSU) avec un prix d’exercice de 0 $
  • Les RSU seront entièrement acquises à la date anniversaire d’un an à compter de la date d’attribution
  • Les actions sous-jacentes ne peuvent être livrées, transférées ou vendues avant la fin du service

Cette attribution semble faire partie du programme de rémunération des administrateurs de la société, représentant une récompense standard pour le service au conseil d’administration. Le dépôt a été soumis par Andrew R. Boll en tant que mandataire de la directrice le 24 juin 2025, dans le délai de déclaration requis. Mme Graves détient ces RSU en propriété directe.

Die Direktorin Adrienne L. Graves von Harrow erhielt am 20. Juni 2025 eine neue Aktienvergütung, wie in dieser Form 4-Meldung berichtet. Die Transaktionsdetails umfassen:

  • Zuteilung von 7.339 Restricted Stock Units (RSUs) mit einem Ausübungspreis von 0 $
  • Die RSUs werden vollständig am einjährigen Jahrestag des Gewährungsdatums vesten
  • Die zugrunde liegenden Aktien können bis zum Ausscheiden aus dem Dienst nicht geliefert, übertragen oder verkauft werden

Diese Zuteilung scheint Teil des Vergütungsprogramms für Direktoren des Unternehmens zu sein und stellt eine übliche Vergütung für die Tätigkeit im Vorstand dar. Die Meldung wurde am 24. Juni 2025 von Andrew R. Boll als Bevollmächtigter für die Direktorin innerhalb des vorgeschriebenen Meldefensters eingereicht. Frau Graves hält diese RSUs im Direktbesitz.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Graves Adrienne L

(Last) (First) (Middle)
C/O HARROW, INC.
1A BURTON HILLS BLVD, SUITE 200

(Street)
NASHVILLE TN 37215

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HARROW, INC. [ HROW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
RSU(1) $0 06/20/2025 A 7,339 (2) (2) Common Stock 7,339 $0 7,339 D
Explanation of Responses:
1. The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered.
2. Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service.
/s/ Andrew R. Boll as Attorney in Fact for Adrienne L. Graves 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Restricted Stock Units (RSUs) did HROW director Adrienne Graves receive on June 20, 2025?

According to the Form 4 filing, HROW director Adrienne L. Graves received 7,339 Restricted Stock Units (RSUs) on June 20, 2025 as a compensatory award for services rendered or to be rendered.

What is the vesting schedule for HROW director Graves' RSU grant?

The RSU award vests in full on the one-year anniversary following the date of grant (June 20, 2025). The underlying shares cannot be delivered, transferred, or sold until the termination of Graves' service with HROW.

What is the exercise price of the RSUs granted to HROW's director Adrienne Graves?

The Restricted Stock Units were granted with an exercise price of $0, as shown in Table II of the Form 4 filing under the 'Conversion or Exercise Price of Derivative Security' column.

Who filed this Form 4 for HROW and what is their role?

The Form 4 was filed by Andrew R. Boll as Attorney in Fact for Adrienne L. Graves, who serves as a Director of Harrow, Inc. (HROW). The form was signed on June 24, 2025.
Harrow Health Inc

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.21B
30.88M
15.85%
57.3%
11.3%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
NASHVILLE